BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee J, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: Classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004;127:S51-5. [DOI: 10.1053/j.gastro.2004.09.015] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol 2015;21:220-9. [PMID: 26523267 DOI: 10.3350/cmh.2015.21.3.220] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
2 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shao J, Meng Q, Li Y. Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma. Onco Targets Ther 2016;9:4265-75. [PMID: 27478384 DOI: 10.2147/OTT.S102858] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Hernández-alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. Annals of Hepatology 2007;6:5-14. [DOI: 10.1016/s1665-2681(19)31948-9] [Cited by in Crossref: 16] [Article Influence: 1.1] [Reference Citation Analysis]
5 Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, Jung NC, Lee WB, Lee HS, Bae YS, Onji M. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol. 2012;41:1601-1609. [PMID: 22971679 DOI: 10.3892/ijo.2012.1626] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 7.3] [Reference Citation Analysis]
6 Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-3884. [PMID: 16799628 DOI: 10.1038/sj.onc.1209550] [Cited by in Crossref: 269] [Cited by in F6Publishing: 260] [Article Influence: 16.8] [Reference Citation Analysis]
7 Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing? J Gastroenterol Hepatol 2009;24:1817-25. [PMID: 20002941 DOI: 10.1111/j.1440-1746.2009.06121.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
8 Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem 2010;285:25859-66. [PMID: 20551310 DOI: 10.1074/jbc.M110.134874] [Cited by in Crossref: 75] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
9 Kumar A, Ito A, Hirohama M, Yoshida M, Zhang KY. Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors. Bioorg Med Chem Lett 2013;23:5145-9. [PMID: 23920437 DOI: 10.1016/j.bmcl.2013.07.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
10 Yang Y, Liang Z, Xia Z, Wang X, Ma Y, Sheng Z, Gu Q, Shen G, Zhou L, Zhu H, Xu N, Liang S. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways. Cell Commun Signal 2019;17:82. [PMID: 31345225 DOI: 10.1186/s12964-019-0392-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
11 Debebe A, Medina V, Chen CY, Mahajan IM, Jia C, Fu D, He L, Zeng N, Stiles BW, Chen CL, Wang M, Aggarwal KR, Peng Z, Huang J, Chen J, Li M, Dong T, Atkins S, Borok Z, Yuan W, Machida K, Ju C, Kahn M, Johnson D, Stiles BL. Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis. Oncogene 2017;36:6020-9. [PMID: 28671671 DOI: 10.1038/onc.2017.207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
12 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
13 Mirzaei R, Afaghi A, Babakhani S, Sohrabi MR, Hosseini-Fard SR, Babolhavaeji K, Khani Ali Akbari S, Yousefimashouf R, Karampoor S. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother 2021;139:111619. [PMID: 33906079 DOI: 10.1016/j.biopha.2021.111619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yang Y, Xia Z, Wang X, Zhao X, Sheng Z, Ye Y, He G, Zhou L, Zhu H, Xu N, Liang S. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds. Mol Pharmacol 2018;94:885-94. [PMID: 29784649 DOI: 10.1124/mol.118.112300] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
15 Pérez de Castro I, Aguirre-Portolés C, Martin B, Fernández-Miranda G, Klotzbucher A, Kubbutat MH, Megías D, Arlot-Bonnemains Y, Malumbres M. A SUMOylation Motif in Aurora-A: Implications for Spindle Dynamics and Oncogenesis. Front Oncol 2011;1:50. [PMID: 22649767 DOI: 10.3389/fonc.2011.00050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
16 Braconi C, Valeri N, Kogure T, Gasparini P, Huang N, Nuovo GJ, Terracciano L, Croce CM, Patel T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2011;108:786-791. [PMID: 21187392 DOI: 10.1073/pnas.1011098108] [Cited by in Crossref: 149] [Cited by in F6Publishing: 145] [Article Influence: 12.4] [Reference Citation Analysis]
17 Petrelli A, Perra A, Cora D, Sulas P, Menegon S, Manca C, Migliore C, Kowalik MA, Ledda-Columbano GM, Giordano S. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology. 2014;59:228-241. [PMID: 23857252 DOI: 10.1002/hep.26616] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 9.6] [Reference Citation Analysis]
18 Lee JS. Genomic profiling of liver cancer. Genomics Inform 2013;11:180-5. [PMID: 24465228 DOI: 10.5808/GI.2013.11.4.180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Zhang F, Cui L, Kuo MD. Diversity of Gene Expression in Hepatocellular Carcinoma Cells. Genomics Proteomics Bioinformatics 2015;13:377-82. [PMID: 26779818 DOI: 10.1016/j.gpb.2015.07.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Semin Oncol. 2012;39:510-521. [PMID: 22846868 DOI: 10.1053/j.seminoncol.2012.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
21 Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Matejka J, Stauber R, Buder R, Grünberger B, Schöniger-Hekele M, Müller C, Peck-Radosavljevic M. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011;34:949-59. [PMID: 21883324 DOI: 10.1111/j.1365-2036.2011.04823.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
22 Sun F, Wang JZ, Luo JJ, Wang YQ, Pan Q. Exosomes in the Oncobiology, Diagnosis, and Therapy of Hepatic Carcinoma: A New Player of an Old Game. Biomed Res Int. 2018;2018:2747461. [PMID: 30148162 DOI: 10.1155/2018/2747461] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
23 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol. 2009;50:604-620. [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011] [Cited by in Crossref: 381] [Cited by in F6Publishing: 361] [Article Influence: 27.2] [Reference Citation Analysis]
24 Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, Ohta T, Kaneko S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 2009;50:100-110. [PMID: 19008011 DOI: 10.1016/j.jhep.2008.07.036] [Cited by in Crossref: 104] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
25 Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Demetris AJ, Nalesnik M, Yu YP. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006;44:1012-1024. [PMID: 17006932 DOI: 10.1002/hep.21328] [Cited by in Crossref: 200] [Cited by in F6Publishing: 216] [Article Influence: 12.5] [Reference Citation Analysis]
26 Koschny R, Brost S, Hinz U, Sykora J, Batke EM, Singer S, Breuhahn K, Stremmel W, Walczak H, Schemmer P, Schirmacher P, Ganten TM. Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. BMC Cancer 2013;13:532. [PMID: 24209510 DOI: 10.1186/1471-2407-13-532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
27 Lee JS, Choi HJ, Baek SH. Sumoylation and Its Contribution to Cancer. Adv Exp Med Biol 2017;963:283-98. [PMID: 28197919 DOI: 10.1007/978-3-319-50044-7_17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
28 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Tomasi ML, Ramani K. SUMOylation and phosphorylation cross-talk in hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:20. [PMID: 29780898 DOI: 10.21037/tgh.2018.04.04] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
30 Bodey B, Bodey B Jr, Siegel SE. Mechanisms and markers of carcinogenesis and neoplastic progression. Expert Opin Biol Ther 2005;5:1317-32. [PMID: 16197337 DOI: 10.1517/14712598.5.10.1317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
31 Chen LZ, Li XY, Huang H, Xing W, Guo W, He J, Sun ZY, Luo AX, Liang HP, Hu J, Wang ZG, Xu YS, Xu X. SUMO-2 promotes mRNA translation by enhancing interaction between eIF4E and eIF4G. PLoS One 2014;9:e100457. [PMID: 24971752 DOI: 10.1371/journal.pone.0100457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics. 2008;5:45-60. [PMID: 18282123 DOI: 10.1586/14789450.5.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
33 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 5.6] [Reference Citation Analysis]
34 Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012;31:4517-4526. [PMID: 22249248 DOI: 10.1038/onc.2011.631] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 5.4] [Reference Citation Analysis]
35 Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol. 2006;33:S79-S83. [PMID: 17178294 DOI: 10.1053/j.seminoncol.2006.10.015.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Sulas P, Di Tommaso L, Novello C, Rizzo F, Rinaldi A, Weisz A, Columbano A, Roncalli M. A Large Set of miRNAs Is Dysregulated from the Earliest Steps of Human Hepatocellular Carcinoma Development. Am J Pathol. 2018;188:785-794. [PMID: 29248455 DOI: 10.1016/j.ajpath.2017.10.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
37 Bermejo JL, Kabisch M, Dünnebier T, Schnaidt S, Melchior F, Fischer H, Harth V, Rabstein S, Pesch B, Brüning T, Justenhoven C, Brauch H, Baisch C, Ko Y, Hamann U. Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases: SUMO isopeptidase gene USPL1 and breast cancer. Int J Cancer 2013;133:362-72. [DOI: 10.1002/ijc.28040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
38 Liu S, Wang L, Jiang D, Wei W, Nasir MF, Khan MS, Yousafi Q, Liu X, Fu X, Li X, Li J. Sumoylation as an Emerging Target in Therapeutics against Cancer. Curr Pharm Des 2020;26:4764-76. [PMID: 32568016 DOI: 10.2174/1381612826666200622124134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798-805. [PMID: 16488507 DOI: 10.1016/j.jhep.2006.01.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
40 Weeda VB, Aronson DC, Verheij J, Lamers WH. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. Pediatr Blood Cancer 2019;66:e27475. [PMID: 30259629 DOI: 10.1002/pbc.27475] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Ong JR, Bamodu OA, Khang NV, Lin YK, Yeh CT, Lee WH, Cherng YG. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma. Cells 2021;10:178. [PMID: 33477333 DOI: 10.3390/cells10010178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
42 Pok S, Wen V, Shackel N, Alsop A, Pyakurel P, Fahrer A, Farrell GC, Teoh NC. Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis. J Gastroenterol Hepatol. 2013;28:1545-1554. [PMID: 23574010 DOI: 10.1111/jgh.12216] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
43 Zhao Q, Ma Y, Li Z, Zhang K, Zheng M, Zhang S. The Function of SUMOylation and Its Role in the Development of Cancer Cells under Stress Conditions: A Systematic Review. Stem Cells Int 2020;2020:8835714. [PMID: 33273928 DOI: 10.1155/2020/8835714] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
45 Teoh NC. Much ado about Nutlin. J Gastroenterol Hepatol 2011;26:213-5. [PMID: 21261708 DOI: 10.1111/j.1440-1746.2010.06588.x] [Reference Citation Analysis]
46 Gal O, Auslander N, Fan Y, Meerzaman D. Predicting Complete Remission of Acute Myeloid Leukemia: Machine Learning Applied to Gene Expression. Cancer Inform 2019;18:1176935119835544. [PMID: 30911218 DOI: 10.1177/1176935119835544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
47 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
49 Zabala M, Lasarte JJ, Perret C, Sola J, Berraondo P, Alfaro M, Larrea E, Prieto J, Kramer MG. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol 2007;47:807-15. [PMID: 17935823 DOI: 10.1016/j.jhep.2007.07.025] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
50 Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-9. [PMID: 16799621 DOI: 10.1038/sj.onc.1209561] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 4.9] [Reference Citation Analysis]
51 Breinig M, Caldas-lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009;50:102-12. [DOI: 10.1002/hep.22912] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
52 Kho C, Lee A, Jeong D, Oh JG, Gorski PA, Fish K, Sanchez R, DeVita RJ, Christensen G, Dahl R, Hajjar RJ. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nat Commun 2015;6:7229. [PMID: 26068603 DOI: 10.1038/ncomms8229] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
53 Siegel AB, Olsen SK, Magun A, Brown RS. Sorafenib: where do we go from here? Hepatology. 2010;52:360-369. [PMID: 20578152 DOI: 10.1002/hep.23633] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
54 Kumar A, Ito A, Hirohama M, Yoshida M, Zhang KYJ. Identification of Sumoylation Activating Enzyme 1 Inhibitors by Structure-Based Virtual Screening. J Chem Inf Model 2013;53:809-20. [DOI: 10.1021/ci300618e] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
55 Martin J, Dufour JF. Abnormal nitrosothiol metabolism in hepatocellular carcinoma. J Hepatol 2011;54:579-80. [PMID: 21112114 DOI: 10.1016/j.jhep.2010.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
56 Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
57 Kowalik MA, Sulas P, Ledda-Columbano GM, Giordano S, Columbano A, Perra A. Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget 2015;6:38749-63. [PMID: 26452031 DOI: 10.18632/oncotarget.5501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
58 Mas VR, Maluf DG, Archer KJ, Yanek K, Williams B, Fisher RA. Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med 2006;12:97-104. [PMID: 16953559 DOI: 10.2119/2006-00032.Mas] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Mattu S, Saliba C, Sulas P, Zavattari P, Perra A, Kowalik MA, Monga SP, Columbano A. High Frequency of β-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist. The American Journal of Pathology 2018;188:2497-507. [DOI: 10.1016/j.ajpath.2018.07.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
61 Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138:958-968. [PMID: 19914252 DOI: 10.1053/j.gastro.2009.11.005] [Cited by in Crossref: 391] [Cited by in F6Publishing: 377] [Article Influence: 30.1] [Reference Citation Analysis]
62 Sarge KD, Park-Sarge OK. Sumoylation and human disease pathogenesis. Trends Biochem Sci 2009;34:200-5. [PMID: 19282183 DOI: 10.1016/j.tibs.2009.01.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 7.8] [Reference Citation Analysis]
63 Brown AL, Conrad K, Allende DS, Gromovsky AD, Zhang R, Neumann CK, Owens AP, Tranter M, Helsley RN. Dietary Choline Supplementation Attenuates High-Fat-Diet-Induced Hepatocellular Carcinoma in Mice. J Nutr 2020;150:775-83. [PMID: 31851339 DOI: 10.1093/jn/nxz315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Nie W, Yan L, Lee YH, Guha C, Kurland IJ, Lu H. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrom Rev. 2016;35:331-349. [PMID: 24890331 DOI: 10.1002/mas.21439] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
65 Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008;8:714-24. [PMID: 19143056 DOI: 10.1038/nrc2401] [Cited by in Crossref: 238] [Cited by in F6Publishing: 228] [Article Influence: 18.3] [Reference Citation Analysis]
66 Berardocco M, Radeghieri A, Busatto S, Gallorini M, Raggi C, Gissi C, D'Agnano I, Bergese P, Felsani A, Berardi AC. RNA-seq reveals distinctive RNA profiles of small extracellular vesicles from different human liver cancer cell lines. Oncotarget 2017;8:82920-39. [PMID: 29137313 DOI: 10.18632/oncotarget.20503] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
67 Teoh N, Pyakurel P, Dan YY, Swisshelm K, Hou J, Mitchell C, Fausto N, Gu Y, Farrell G. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis. Gastroenterology. 2010;138:1155-1165.e1-2. [PMID: 19919837 DOI: 10.1053/j.gastro.2009.11.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
68 Kumar R, Sabapathy K. RNF4—A Paradigm for SUMOylation‐Mediated Ubiquitination. Proteomics 2019;19:1900185. [DOI: 10.1002/pmic.201900185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
69 Son G, Kremer M, Hines IN. Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract. 2010;2010:453563. [PMID: 20706692 DOI: 10.1155/2010/453563] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
70 Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014;60:855-65. [PMID: 24308993 DOI: 10.1016/j.jhep.2013.11.031] [Cited by in Crossref: 161] [Cited by in F6Publishing: 168] [Article Influence: 17.9] [Reference Citation Analysis]
71 Lee HS, Lim YS, Park EM, Baek SH, Hwang SB. SUMOylation of nonstructural 5A protein regulates hepatitis C virus replication. J Viral Hepat. 2014;21:e108-e117. [PMID: 24602294 DOI: 10.1111/jvh.12241] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
72 Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene. 2011;30:4175-4184. [PMID: 21499307 DOI: 10.1038/onc.2011.126] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
73 Kim B, Suh K, Lee J, Woo SR, Park I, Park S, Han CJ, Kim S, Jeong S, Yeom YI, Yang S, Kim C, Cho SJ, Yoo YD, Cho M, Jang JJ, Choi DW, Lee K. Integrated Analysis of Prognostic Gene Expression Profiles from Hepatitis B Virus-Positive Hepatocellular Carcinoma and Adjacent Liver Tissue. Ann Surg Oncol 2012;19:328-38. [DOI: 10.1245/s10434-011-1709-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
74 Hernandez-Alcoceba R, Sangro B, Prieto J. Gene therapy of liver cancer. World J Gastroenterol 2006; 12(38): 6085-6097 [PMID: 17036377 DOI: 10.3748/wjg.v12.i38.6085] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
75 Rodriguez-Madoz JR, Zabala M, Alfaro M, Prieto J, Kramer MG, Smerdou C. Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Hum Gene Ther 2014;25:132-43. [PMID: 24219025 DOI: 10.1089/hum.2013.080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
76 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.1] [Reference Citation Analysis]
77 Ho C, Lin K, Shen R, Gu D, Lee S, Su W, Jou Y. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.008] [Reference Citation Analysis]
78 Song MS, Jeong JS, Ban G, Lee JH, Won YS, Cho KS, Kim IH, Lee SW. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Cancer Gene Ther. 2009;16:113-125. [PMID: 18758435 DOI: 10.1038/cgt.2008.64] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
79 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
80 Yang Y, He Y, Wang X, Liang Z, He G, Zhang P, Zhu H, Xu N, Liang S. Protein SUMOylation modification and its associations with disease. Open Biol 2017;7:170167. [PMID: 29021212 DOI: 10.1098/rsob.170167] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 17.8] [Reference Citation Analysis]
81 Sarge KD, Park-Sarge OK. SUMO and its role in human diseases. Int Rev Cell Mol Biol 2011;288:167-83. [PMID: 21482412 DOI: 10.1016/B978-0-12-386041-5.00004-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
82 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
83 Furusyo N, Takeoka H, Toyoda K, Murata M, Tanabe Y, Kajiwara E, Shimono J, Masumoto A, Maruyama T, Nomura H, Nakamuta M, Takahashi K, Shimoda S, Azuma K, Sakai H, Hayashi J, Group TKULDS. Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University Liver Disease Study. World J Gastroenterol 2006; 12(4): 561-567 [PMID: 16489669 DOI: 10.3748/wjg.v12.i4.561] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
84 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
85 Maillard E. [Epidemiology, natural history and pathogenesis of hepatocellular carcinoma]. Cancer Radiother 2011;15:3-6. [PMID: 21239205 DOI: 10.1016/j.canrad.2010.11.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
86 Watts FZ. Starting and stopping SUMOylation. What regulates the regulator? Chromosoma 2013;122:451-63. [PMID: 23812602 DOI: 10.1007/s00412-013-0422-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
87 Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012;55:1443-1452. [PMID: 22105560 DOI: 10.1002/hep.24813] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
88 Ahronian LG, Zhu LJ, Chen YW, Chu HC, Klimstra DS, Lewis BC. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene. 2016;35:4653-4662. [PMID: 26876204 DOI: 10.1038/onc.2016.2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
89 Mah WC, Lee CG. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomark Res. 2014;2:5. [PMID: 24635883 DOI: 10.1186/2050-7771-2-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
90 Li Z, Zheng W, Wang Z, Zeng Z, Zhan H, Li C, Zhou L, Yan C, Spitsbergen JM, Gong Z. A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. Dis Model Mech. 2013;6:414-423. [PMID: 23038063 DOI: 10.1242/dmm.010462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
91 Hua D, Wu X. Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases. Eur J Med Chem 2022;233:114227. [PMID: 35247754 DOI: 10.1016/j.ejmech.2022.114227] [Reference Citation Analysis]
92 Wang C, Xiao Y, Lao M, Wang J, Xu S, Li R, Xu X, Kuang Y, Shi M, Zou Y, Wang Q, Liang L, Zheng SG, Xu H. Increased SUMO-activating enzyme SAE1/UBA2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synoviocytes. JCI Insight 2020;5:135935. [PMID: 32938830 DOI: 10.1172/jci.insight.135935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
93 Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3. [PMID: 17244360 DOI: 10.1186/1479-5876-5-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
94 Adebayo Michael AO, Ahsan N, Zabala V, Francois-Vaughan H, Post S, Brilliant KE, Salomon AR, Sanders JA, Gruppuso PA. Proteomic analysis of laser capture microdissected focal lesions in a rat model of progenitor marker-positive hepatocellular carcinoma. Oncotarget 2017;8:26041-56. [PMID: 28199961 DOI: 10.18632/oncotarget.15219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
95 Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T, Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 2012;14:410-9. [PMID: 22745587 DOI: 10.1596/neo.111366] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
96 Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20. [PMID: 19216803 DOI: 10.1186/1756-9966-28-20] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
97 Lv C, Wang S, Lin L, Wang C, Zeng K, Meng Y, Sun G, Wei S, Liu Y, Zhao Y. USP14 maintains HIF1-α stabilization via its deubiquitination activity in hepatocellular carcinoma. Cell Death Dis 2021;12:803. [PMID: 34420039 DOI: 10.1038/s41419-021-04089-6] [Reference Citation Analysis]
98 Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol. 2005;43:863-874. [PMID: 16139920 DOI: 10.1016/j.jhep.2005.05.033] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
99 Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K, Matsui O, Kaneko S. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2010;126:2164-2174. [PMID: 19739081 DOI: 10.1002/ijc.24882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
100 Kumar A, Ito A, Hirohama M, Yoshida M, Zhang KY. Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping. Bioorganic & Medicinal Chemistry Letters 2016;26:1218-23. [DOI: 10.1016/j.bmcl.2016.01.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
101 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 228] [Article Influence: 16.2] [Reference Citation Analysis]
102 Critelli R, Milosa F, Faillaci F, Condello R, Turola E, Marzi L, Lei B, Dituri F, Andreani S, Sighinolfi P, Manni P, Maiorana A, Caporali C, di Benedetto F, Del Buono M, De Maria N, Schepis F, Martinez-Chantar ML, Giannelli G, Villa E. Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. Cell Death Dis 2017;8:e3017. [PMID: 28837142 DOI: 10.1038/cddis.2017.395] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
103 Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, Thorgeirsson SS. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51:1401-1409. [PMID: 20054870 DOI: 10.1002/hep.23488] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 7.9] [Reference Citation Analysis]
104 Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma. Hepatology 2014;60:452-4. [PMID: 24644061 DOI: 10.1002/hep.27081] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
105 Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol. 2006;33:S79-S83. [PMID: 17178294 DOI: 10.1053/j.seminoncol.2006.10.015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
106 Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, Yamada-okabe H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006;132:473-81. [DOI: 10.1007/s00432-006-0094-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
107 Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007;133:1475-1486. [PMID: 17983802 DOI: 10.1053/j.gastro.2007.08.038] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
108 Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opinion on Emerging Drugs 2006;11:469-87. [DOI: 10.1517/14728214.11.3.469] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
109 Wu J, Du J, Liu L, Li Q, Rong W, Wang L, Wang Y, Zang M, Wu Z, Zhang Y. Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One. 2012;7:e50035. [PMID: 23227158 DOI: 10.1371/journal.pone.0050035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
110 Turato C, Cannito S, Simonato D, Villano G, Morello E, Terrin L, Quarta S, Biasiolo A, Ruvoletto M, Martini A, Fasolato S, Zanus G, Cillo U, Gatta A, Parola M, Pontisso P. SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity. Sci Rep 2015;5:17701. [PMID: 26634820 DOI: 10.1038/srep17701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
111 Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410-416. [PMID: 16532004 DOI: 10.1038/nm1377] [Cited by in Crossref: 677] [Cited by in F6Publishing: 641] [Article Influence: 42.3] [Reference Citation Analysis]
112 Hung PF, Hong TM, Chang CC, Hung CL, Hsu YL, Chang YL, Wu CT, Chang GC, Chan NL, Yu SL, Yang PC, Pan SH. Hypoxia-induced Slug SUMOylation enhances lung cancer metastasis. J Exp Clin Cancer Res 2019;38:5. [PMID: 30612578 DOI: 10.1186/s13046-018-0996-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
113 Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13(16): 2271-2282 [PMID: 17511024 DOI: 10.3748/wjg.v13.i16.2271] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 82] [Article Influence: 5.9] [Reference Citation Analysis]